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Abstract
Background
The emerging chikungunya virus (CHIKV), is an arbovirus causing intense outbreaks in
North America. The situation in Mexico is alarming, and CHIKV threatens to spread further
throughout North America. Clinical and biological features of CHIKF outbreaks in Mexico
have not been well described; thus, we conducted a cross sectional study of a CHIKV out-
break in Chiapas, Southern Mexico to further characterize these features.
Methodology/Principal findings
We collected blood samples from patients suspected of having chikungunya fever (CHIKF)
who presented to Clinical Hospital ISSSTE Dr. Roberto Nettel in Tapachula, Chiapas,
Mexico. In addition to the clinical examination, real-time polymerase chain reaction (PCR)
standardized for the Asian Chikungunya lineage and/or enzyme-linked immunosorbent
assay for immunoglobulin M (IgM) were used to confirm CHIKV diagnosis. Of a total of 850
patients who presented with probably CHIKV at Hospital “Dr. Roberto Nettel”, 112 probable
CHIKF cases were enrolled in this study from November 2014- June 2015, of which 95
patients (84.8%) were CHIKV positive and 17 were negative (15.2%). Of these 95 CHIKV
positive patients, 62 were positive by real-time reverse transcriptase PCR (+qRT-PCR);
and 33 were seropositive to +IgM with a negative qRT-PCR. The most frequent symptoms
reported were fever (100%), headache (82.3%), polyarthralgia (72.1%), and exanthem
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(82.3%). Biological abnormalities observed during CHIKV infection were lymphopenia
(41.1%), leukopenia (51.6%), elevated transaminases (30.5%-46.3%) and high LDH
(46.3%) and CRP (60.0%).
Conclusion
Clinical and biological data obtained from this study is providing more useful information for
benchmarking purposes with outbreaks from different parts of the world and would be help-
ful for better patient care and treatment.
Introduction
Chikungunya virus (CHIKV) is a febrile threat that has been attacking the New World since
2013. Chikungunya fever (CHIKF) is caused by the chikungunya virus (CHIKV) that belongs
to the Togaviridae family, Alphavirus genus, and is transmitted by the Aedes aegypti and Aedes
albopictus mosquitoes [1]. Since its introduction to the New World, CHIKV has caused
impressive outbreaks throughout the American continents, with 1,118,763 cases during the
2013–2014 epidemics [2]. In the following years, CHIKF has caused 575,281 cases in 2015;
998,015 cases in 2016 and 140,550 cases up to epidemiological week 30 in 2017, affecting
mainly in Central America and South America [3]. After a year of chikungunya emergence in
the Americas, this arbovirus entered Mexico in October 2014 through the Mexico-Guatemala
border in Chiapas State [4], but was not reported officially until November of the same year
[5]. In Mexico, the Asian genotype of the CHIKV is circulating, and transmission is con-
strained to Ae. aegypti [6–8]. The Asian tiger mosquito, Ae. albopictus, has not been identified
as a vector of CHIKV and Ae. albopictus-adaptive mutations have not appeared yet in Mexico
[4,9]. Since its introduction to Mexico, CHIKV has followed three paths of spread emergence
from its point of entry, Chiapas State: along the Pacific coast, the Gulf of Mexico coast, and the
Yucatan Peninsula. During the 2015 outbreak, through epidemiological week 38, the most
affected States were Guerrero (20.4%), Michoaca´n (15.4%), Oaxaca (14.8%), and Veracruz
(11.8%), while the remaining cases (37.6%) were distributed mainly in the states of Chiapas,
Colima, Yucata´n, Morelos, and Campeche [10].
The clinical manifestations of CHIKV are well described in previous studies and reports
of the outbreaks in Africa [11–14], Europe [15], and Asia [16–18]. Of the outbreaks in the
Americas, only CHIKF outbreaks in Colombia, Trinidad and Grenada have been described
in detail [19–21]. Typically, the onset of CHIKF is abrupt and includes the following symp-
toms: fever, severe polyarthralgia, headache, back pain, and myalgia. Fever is generally the
first symptom to appear; the other symptoms follow within a few days. Arthralgia usually
affects more than one joint; and the most affected joints are the knees, ankles, hands, and
wrists. The symptoms typically resolve within 7–10 days, although joint pains can last weeks,
months, or years. Laboratory features during a CHIKV infection have been described in
reports from various outbreaks. The most significant features seen in CHIKV-positive
patients are lymphopenia, leukopenia, hypocalcemia, and elevated transaminases; but these
features were not consistently reported in all studies and vary depending the clinical phase of
infection [12,13,20,22]. Clinical variation could be explained by unique immunopathogenic
responses of the two CHIKV genotypes. Evidence of the lesser virulence and pathogenicity
of the Caribbean lineage (Asian genotype) compared with the Indian Ocean lineage, which
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evolved from the Eastern/Central/Southern African (ECSA) genotype, was recently obtained
using a mouse infection model [23].
The clinical presentation good outcomes based on genotype/lineage have been poorly dis-
cussed. This study is an attempt to document and describe the clinical and biological features
of CHIKV outbreak caused by the Caribbean linage in Mexico. In addition, we compared clin-
ical descriptions of outbreaks caused by the ECSA-IOL and Asian genotype worldwide with
the results obtained in our study. We conducted a cross-sectional observational study in a sec-
ondary healthcare hospital in Tapachula, Chiapas, Mexico, at which probable CHIKV cases
were recruited and then diagnosed by molecular and serological testing. Additionally, clinical
symptomatology was recorded by each enrolled patient and then blood cell count and bio-
chemical analysis were performed to obtained relevant biological data related to CHIKV
infection.
Methods
Study area
A cross-sectional and observational study was carried between December 2014 and June 2015
in the Clinical Hospital “Dr. Roberto Nettel Flores” located in the city of Tapachula (14˚56’ N,
92˚17’ W), Chiapas State, near 15km from the Mexico-Guatemala border. This hospital
attends patients form Soconusco region, composed by Tapachula and other 15 municipalities:
Metapa, Acapetahua, Acacoyagua, Escuintla, Frontera Hidalgo, Huehuetan, Huixtla, Union
Juarez, Mazatan, Cacahoatan, Villa Comatitlan, Suchiate, Tuxtla Chico, Tuzantan and Mapas-
tepec. This region has a population of 728,647, and dengue fever (DENF) has been historically
endemic [24,25] in this area.
Ethical considerations
The study was approved by the Bioethical Committee of the National Institute of Public Health
(Project #1312 and approval #1738). Patients were enrolled in the study during a CHIKV out-
break, and blood samples were collected as part of the routine laboratory analysis of patients
admitted to Hospital Dr. Roberto Nettel (S1 File). Therefore, only an oral consent to partici-
pate in the study was obtained from each patient. All pertinent information about the study
(purpose, procedures, risks, benefits, alternatives to participation, etc.) was explained to poten-
tial participants in the presence of an independent witness, and every patient who agreed to
participate was recorded in an intake form by the hospital’s Epidemiology Department [26].
Study population and recruitment
The Hospital “Dr. Roberto Nettel” attends only State workers and their immediate relatives
who represent 4.5% of the total population of Soconusco Region [27]. Patients who were
admitted in this hospital were included in the study if their clinical symptoms met the follow-
ing inclusion criteria for suspicion of CHIKF: acute onset of fever >38.5˚C accompanied by
severe arthralgia not explained by other medical conditions in patients residing in the epi-
demic area [28]. Exclusion criteria were if patients disagree to participate in the study or were
DENV-positive by RT-PCR or ELISA.
Clinical examination and blood collection
After enrollment, a clinical examination was performed following the epidemiological case
study format for CHIKV provided by the General Direction of Epidemiology, Ministry of
Health [26]. This format collects presence or absence of following symptoms: fever,
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polyarthralgia, arthritis, headache, myalgia, edema, exanthema, adenopathies, retroorbital
pain, digestive alterations (vomiting, diarrhea, and nausea), etcetera. To avoid any confusion
between polyarthralgia and arthritis, we differentiated them being the first a transient, inter-
mittent, or persistent pain in multiple joints while the second is the inflammation of one or
more joints. Additional epidemiological data such as patient age, gender and travel history is
also included. After the clinical examination, the physician filled the format by patient and
then collected three blood samples from each patient: one tube with EDTA for a complete
blood cell count and one tube with citrate and one dry-tube for the remaining laboratory tests.
Dry-tubes were centrifuged at 3,000 rpm, and serum was aliquoted and stored at −80˚C for
testing.
Clinical laboratory analysis
Hematological parameters including erythrocytes, hemoglobin, hematocrit, mean corpuscular
volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, white
blood cells (WBC), mean platelet volume, and red cell distribution width were determined
using a hematology analyzer Advia1 120 (Siemens Healthcare Diagnostics, Erlangen, Ger-
many). Other parameters, including differential WBC (%), prothrombin time (PT), activated
partial thromboplastin time (PTT), and fibrinogen, were determined using a coagulation ana-
lyzer IL ACL Elite PRO (Diamond1 Diagnostics, Holliston, MA). Laboratory assessment of
liver function was determined by measuring aspartate aminotransferase (AST), alanine amino-
transferase (ALT), alkaline phosphatase (ALP), lactate dehydrogenase (LDH), γ-glutamyltrans-
ferase, total protein, albumin, globulin, albumin/globulin ratio, total bilirubin, direct bilirubin,
and indirect bilirubin using an Integrated Chemistry System Dimension1 RxL Max1 (Sie-
mens Healthcare Diagnostics, Erlangen, Germany). Others biochemical parameters, including
glucose, urea, creatinine, uric acid, triglycerides, total cholesterol, serum electrolytes (sodium,
chloride, and potassium), and inflammatory marker C-reactive protein (CRP) were measured
using Dimension1 RxL Max1.
Diagnostic qRT-PCR and serology
RNA was extracted from 140μL of serum from each sample using the QIAmp1 Viral RNA
Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol. For molecular
diagnostics, one-step qRT-PCR was performed according to the Center of Disease Control
(CDC) protocol using primers and probe designed for Caribbean lineage (Asian genotype)
[29]: 1) we used the primers CHIK 856 5’-ACCATCGGTGTTCCATCTAAAG-3’ and CHIK
962c 5’-GCCTGGGCTCATCGTTATT-3’ and the TaqMan Probe CHIK 908 5’-FAM-
ACAGTGGTTTCGTGTGAGGGCTAC-NFQ-3´; 2) the qRT-PCR was prepared with the QIA-
GEN QuantiTect Probe RT-PCR kit1 (Qiagen, Venlo, Netherlands) in accordance with the
manufacturer’s protocol, adding 10μL of RNA sample per reaction in duplicate; and 3) the
samples were run in the 7500 Fast Real Time PCR System (Applied Biosystems, Foster City,
CA). Thermal cycling conditions were: one cycle of 50˚C for 30 minutes and 95˚C for 15 min-
utes followed by 45 cycles of 95˚C for 15 seconds and 60˚C for 60 seconds. The cycle threshold
(CT) value was 38: results were considered positive if less than 38 cycles were needed in both
wells; negative if greater than 38 cycles were needed in both wells, and equivocal if less than 38
cycles were needed in one of the two wells. Serum samples were screened for anti-CHIKV IgM
antibodies by enzyme-linked immunosorbent assay (ELISA) as previously described [30,31]
using the CHIKjj Detect MAC-ELISA kit (InBios, Inc., Seattle, WA). All samples were tested
in duplicate and any inconclusive samples were retested.
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For dengue diagnosis, the samples were separately sent to the State Laboratory of Public
Health of Chiapas. Serum was tested with Panbio1 Dengue Early ELISA and Panbio1 Dengue
IgM Capture ELISA (Alere, Waltham, MA) for detection of NS1 antigen and IgM antibody fol-
lowing the manufacturer’s protocol.
Results
Ministry of Health reported 2,500 probable chikungunya cases distributed in Soconusco
Region from November 2014 to June 2015, of which 850 were admitted by Hospital “Dr.
Roberto Nettel”. Of these patients, only 112 agreed to enrollment in this study (Fig 1). Com-
plete clinical, epidemiological, and biochemical data were obtained from each participant; and
none was excluded because of missing data. Ninety-five patients had confirmed CHIKF with
62 being +qRT-PCR and 33 +IgM/-qRT-PCR, while the remaining 17 patients were CHIKV-
negative (Fig 1). Only one patient was qRT-PCR and IgM positive and was categorized as a
viremic case in subsequent data analysis. None of the confirmed CHIKV cases was DENV-
positive by NS1 or IgM ELISA. Confirmed CHIKV cases from this study were distributed
across nine municipalities, with the greatest number of cases in Tapachula (39 cases, 41.0%),
Tuxtla Chico (17 cases, 17.9%), Huehuetan (17 cases, 17.9%), and Cacahoatan (11 cases,
11.6%). Data are shown only for viremic and post-viremic cases because the numbers of nega-
tive cases were too few (17 cases) for meaningful analysis.
Demographic data for the 95 patients with confirmed CHIKV are shown in Table 1. The
mean age of patients was similar at 37.2 and 39.2 years for viremic and post-viremic patients,
respectively. The age groups most affected by CHIKV infection were adults 31–40 and 41–50
years, together accounting for almost half of the CHIKV cases in both phases of disease; how-
ever, minors (<20 years) accounted for 12.6% of confirmed cases in both stages. Furthermore,
sex distribution was unequal showing a male/female rate of 0.4. Approximately 70% of patients
in both phases of disease were female (Table 1).
An extensive clinical description of the patients during the viremic and post-viremic phases
is described in Table 2. The timing of clinical data and blood collection was an important issue
considered in the study. The median numbers of days between symptom onset and consulta-
tion (SOC) were 3.0 and 4.0 for viremic and post-viremic patients, respectively. Despite this
short time difference in SOC between both phases, we observed some interesting differences
in clinical and laboratory features between the disease phases. The most common symptoms
recorded during the viremic stage were fever (100%), polyarthralgia (100.0%), headache
(82.3%), exanthem (82.3%), chills (82.3%), and nausea (71.0%). Other symptoms often
observed in the viremic patients included pruritus (66.1%), arthritis (58.1%), abdominal pain
(46.8%), edema (43.5%) and diarrhea (33.9%). On the other hand, the most frequent symp-
toms described in post-viremic patients were polyarthalgia (100%), headache (87.9%), exan-
thema (81.8%), chills (75.8%), and nausea (48.5%) and other symptoms developed, such as
arthritis (78.8%) and adenopathy (60.6%). The only symptoms that showed substantial differ-
ences between phases were arthritis, adenopathy, and nausea (Table 2).
Regarding laboratory studies, serum samples were tested for different features: blood cell
count, carbohydrates, lipids, electrolytes, inflammatory marker, and hepatic and renal func-
tions. These tests were performed to find any alteration caused by CHIKV infection in the
viremic and post-viremic patients, and the results are shown in Figs 2 and 3. Most parameters
measured in this study fell within normal ranges in both phases except for hepatic enzymes
(AST, ALT, ALP), absolute count of white cells, lymphocytes, LDH and CRP. Of these features,
however, notable differences between the two phases were observed in lymphocyte count,
LDH and CRP levels. Although differences between the phases were also observed in
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triglycerides, PT, and PTT, these results were not relevant because most of the values were
within normal ranges. Table 3 demonstrates the relevant abnormalities in laboratory values
with the respective reference values included. Elevated concentration of hepatic enzymes
(AST, ALT, ALP) was seen in approximately 30.6–48.4% and 24.4–42.4% of viremic and post-
viremic patients, respectively. Low white cell counts occurred in 60–70% of cases in both dis-
ease stages, and lymphopenia was significantly more frequent in viremic patients (56.6%) than
in post-viremic patients (12.1%). Moreover, LDH levels were significantly more frequent in
post-viremic patients (69.7%) than in viremic patients (33.9%). CRP was expectedly elevated
in the viremic patients of infection (61.0%) but normal in all post-viremic patients.
Discussion
At the end of 2014, chikungunya virus emerged in Mexico and, since then, have caused out-
breaks in the states along the Pacific and Gulf of Mexico coasts. Previous sequencing data
Table 1. Demographic data from the 95 enrolled patients.
Viremic (+qRT-PCR) Post-viremic (+IgM) Total
Data population Mean 95% CI Mean 95% CI Media 95% CI
Age 37.2 ± 3.7 39.2 ± 5.1 37.9 ±3.0
Age groups N % N % N %
0–20 y 8 12.9 4 12.1 12 12.6
21–30 y 10 16.1 5 15.2 15 15.8
31–40 y 13 21.0 8 24.2 21 22.1
41–50 y 18 29.0 9 27.3 27 28.4
>50 y 13 21.0 7 21.2 20 21.1
Sex N % N % N %
Female 44 71.0 24 72.7 68 71.6
Male 18 29.0 9 27.3 27 28.4
Abbreviations: qRT-PCR, real-time reverse transcriptase polymerase chain reaction; IgM, immunoglobulin M; CI, confidence interval.
https://doi.org/10.1371/journal.pone.0186923.t001
Fig 1. Patient enrollment in Hospital Dr. Roberto Nettel for clinical and laboratory evaluation of the 95 confirmed CHIKF cases.
Abbreviation: CHIKF, chikungunya fever.
https://doi.org/10.1371/journal.pone.0186923.g001
Clinical description of CHIKF in Mexico
PLOS ONE | https://doi.org/10.1371/journal.pone.0186923 October 24, 2017 6 / 15
suggests that the CHIKV entered the country through the Mexico-Guatemala border in Chia-
pas [4]. Precisely in this point of entry, we conducted clinical and laboratory evaluation of 112
patients with symptoms concerning for CHIKF, confirming 95 cases by qRT-PCR and ELISA.
Depending on whether the patient was qRT-PCR or IgM positive, the patient was placed into
one of two groups, the viremic patients group or the post-viremic patients group. From these
patients, we analyzed data from the clinical data and laboratory tests; described basic demo-
graphic information, such as age and gender.
The key results were as follows: 1) of 112 probable CHIKF cases, 95 cases (84.8%) were con-
firmed by qRT-PCR (33) or IgM ELISA (62) being adults and females more affected; 2) fever,
polyarthralgia, exanthem, and headache were the most common symptoms observed in
patients, however, adenopathies that had not been deeply described in previous studies were
also found in our study, 3) in the disease onset, symptomatology between previous IOL
Table 2. Clinical features of the 95 confirmed CHIKV cases separated by phase of infection, viremic or post-viremic.
Viremic (+qRT-PCR) Post-viremic (+IgM) Total
Median 95% CI Median 95% CI Median 95% CI
Days between onset of symptoms and consultation 3.0 2.0–3.0 4.0 2.0–4.0 3.0 2.0–3.0
Clinical features N % N % N %
Fever 62 100 33 100 95 100
Headache 51 82.3 29 87.9 80 84.2
Myalgia 4 6.5 0 0.0 4 4.2
Polyarthralgia 62 100 33 100 95 100
Arthritis 36 58.1 26 78.8 62 65.3
Retroorbital pain 9 14.5 3 9.1 12 12.6
Exanthem 51 82.3 27 81.8 78 82.1
Pruritus 41 66.1 26 78.8 67 70.5
Vomiting 11 17.7 1 3.0 12 12.6
Nausea 44 71.0 16 48.5 60 63.2
Chills 51 82.3 25 75.8 76 80.0
Photophobia 1 1.6 0 0.0 1 1.1
Abdominal pain 29 46.8 12 36.4 41 43.2
Diarrhea 21 33.9 14 42.4 35 36.8
Conjunctivitis 10 16.1 5 15.2 15 15.8
Nasal congestion 9 14.5 9 27.3 18 18.9
Cough 9 14.5 4 12.1 13 13.7
Pharyngitis 11 17.7 5 15.2 16 16.8
Splenomegaly 1 1.6 0 0.0 1 1.1
Altered taste 49 79.0 23 69.7 72 75.8
Adenopathy 21 33.9 20 60.6 41 43.2
Eyelid inflammation 4 6.5 1 3.0 5 5.3
Dyspnea 4 6.5 1 3.0 5 5.3
Cardiac alteration 1 1.6 0 0.0 1 1.1
Muscle weakness 15 24.2 5 15.2 20 21.1
Petechiae 0 0.0 1 3.0 1 1.1
Edema 27 43.5 17 51.5 44 46.3
Bleeding 3 4.8 2 6.1 5 5.3
Abbreviations: CHIKV, chikungunya virus; CHIKF, chikungunya fever; qRT-PCR, real-time reverse transcriptase polymerase chain reaction; IgM,
immunoglobulin M; CI, confidence interval.
https://doi.org/10.1371/journal.pone.0186923.t002
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outbreaks and Mexican outbreak caused by Asian lineage seems to be similar and 4) biological
abnormalities observed during CHIKV infection were lymphopenia, leukopenia, elevated
transaminases and high LDH and CRP.
In comparing our results to previously report epidemiological data from other outbreaks,
six of nine studies found that the mean or median of age of infected patients was between 30–
40 years, which was similar to the mean age of 37.9 years in our study. Most infected patients
in most other studies were adults between 20–40 years with percentages between 30 to 50%,
with lower frequencies in the elderly and children such as our study. However, two outbreaks
from La Reunion Island reported that elderly people between 50–60 years were most affected.
Lack of herd immunity in the region may explain why CHIKV infections occurred more often
in adults than in old and young patients [32].
The male-to-female ratio in confirmed CHIKV cases has varied. While Thiberville et al.
(2009), Reller et al. (2013), and Win et al. (2010) found a higher proportion of affected males,
Mattar et al. (2015), Sahadeo et al. (2015), Macpherson et al. (2016) and our study found a
higher proportion of infected females. Biased sampling may explain differences among these
studies: i.e., Win et al. (2010) selected more immigrant male workers; and Thiberville et al.
Fig 2. Laboratory values for hepatic and renal function, glucose, lipids, and electrolytes from the 95 confirmed CHIKF cases
enrolled in this study. Black bars indicate viremic patients, while grey bars represent post-viremic patients.
https://doi.org/10.1371/journal.pone.0186923.g002
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(2009), Matter et al. (2015), and Sahadeo et al. (2015) each had low numbers of study partici-
pants, suggesting that their results are not representative of the general population. The sample
obtained for this study is also non-representative and male-to-female ratio of total of probable
cases (850 cases) was 0.5 while the ratio of enrolled participants was 0.4 (112 cases). However,
Fig 3. Laboratory values for blood cell counts, coagulation tests, and an inflammatory marker from the 95 confirmed CHIKF cases
enrolled in this study. Black bars indicate viremic patients, while grey bars represent post-viremic patients.
https://doi.org/10.1371/journal.pone.0186923.g003
Table 3. Biochemical, electrolytic, and hematologic abnormalities observed in the 95 confirmed CHIKV cases.
Viremic Post-viremic Total
N % N % N %
High AST (>37 U/L) 30 48.4 14 42.4 44 46.3
High ALT (>65 U/L) 19 30.6 11 33.3 30 31.6
High ALP (>136 U/L) 21 33.9 8 24.2 29 30.5
High GGT (>85 U/L) 23 37.1 10 30.3 33 34.7
High LDH 21 33.9 23 69.7 44 46.3
Low A/G (<1.2) 44 71.0 27 81.8 71 74.7
Leukopenia (<4500 cells/mm3) 34 54.8 15 45.5 49 51.6
Lymphopenia (<1000 cells/mm3) 35 56.5 4 12.1 39 41.1
Monocytopenia (<200 cells/mm3) 13 21.0 4 12.1 17 17.9
Thrombocytopenia (<100 x 103 platelets/mm3) 11 17.7 5 15.2 16 16.8
Low Hematocrit (<40.0%) 25 40.3 8 24.2 33 34.7
High CRP (>3 mg/dL) 38 61.3 0 0% 38 40.0
Hyponatremia (<136 mEq/L) 9 14.5 5 15.2 14 14.7
Hyperkalemia (>5.1 mEq/L) 10 16.1 12 36.4 22 23.2
Hypochloremia (<98 mEq/L) 9 14.5 4 12.1 13 13.7
Abbreviations: CHIKV, chikungunya virus; CHIKF, chikungunya fever; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline
phosphatase; GGT, γ-glutamyltransferase; LDH, lactate dehydrogenase; A/G, albumin/globulin ratio; CRP, C reactive protein.
https://doi.org/10.1371/journal.pone.0186923.t003
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it is important to consider that CHIKV transmission might have occurred more in home-envi-
ronments putting housewives at major risk of infection, such as was described in previous
reports of dengue seroprevalence in Mexico [33].
The most common symptoms reported by all previous studies including ours were fever
(80–100%), polyarthralgia (80–100%), headache (50–80%), rash (30–70%), and digestive alter-
ations (20–80%). Adenopathy, arthritis, and edema were rarely described in these studies. It is
important to point out that exanthem was very high (82.3%) in our study compared with the
rest of studies that is seen up to 50% of patients [34].
Cervical lymphadenopathies were observed in Indian CHIKV outbreaks and imported
Spanish cases as well as in patients affected by the O’nyong-nyong virus, a related alphavirus
[35–37]. Interestingly, Staikowsky et al. (2009) observed an increase of adenopathies from
8.9% in the viremic patients to 29.0% in the post-viremic patients of CHIKV, similar to our
study from 33.3% in the viremic phase to 60.6% in the post-viremic phase. The occurrence of
lymphadenopathy possibly may have been underdiagnosed in the rest of studies, given that it
may occur toward the end of the febrile period, during recovery from the infection, and
appears to be self-limiting [37]. Unfortunately, the specific location of adenopathies has not
been not recorded in most of studies and neither have we in this study. Regarding arthritis
and edema, the lack of sufficient data makes determining the prevalence of these symptoms
difficult.
Data including viral genotype from the La Reunion Island, Singapore, Gabon, Sri Lanka,
Colombia, and Trinidad & Tobago outbreaks are included in Table 4. Although the Caribbean
Asian lineage of CHIKV has been reported as less virulent than the IOL lineage [23], the Asian
lineage outbreak from Chiapas and the rest of the ECSA-diverged IOL outbreaks worldwide
appear to behave clinically similarly during the first 3–4 days of infection.
Hepatic function was evaluated in this study by measuring the levels of AST, ALT, and
ALP. Studies of the outbreaks in La Reunion Island and Gabon reported elevations of these
enzymes in approximately 20–46% of cases with AST levels up to 55 and 53.2 U/L in viremic
and post-viremic patients, respectively. Our study observed elevations of these enzymes in
approximately 30–50% and 24–43% of viremic and post-viremic cases, respectively. Our
results are quite similar to those previously reported in the literature, but this increase may be
explained by the use of paracetamol and/or ibuprofen for the treatment of symptoms, produc-
ing transient drug toxicity in the liver [11]. Another biological feature that has been associated
with CHIKV infection is elevated C-reactive protein. Previous studies from the outbreak in La
Reunion Island reported high levels of CRP in approximately 50–70% of CHIKF cases, with
serum levels up to 5.6 mg/L, similar to the elevated levels of CRP we found in 61.3% of patients
disease. Additionally, another enzyme observed raised was LDH in post-viremic patients. This
was previously observed elsewhere [38,39] and explained because this enzyme is released into
the extracellular environment during cellular injury associated with inflammation [40].
The blood cell count parameters that were abnormally decreased during CHIKV infection
were absolute counts of leukocytes and lymphocytes, which occurred in 54.8% and 56.5% of
cases, respectively. In post-viremic cases, leukopenia persisted in 45.5% while lymphopenia
decreased to 12.1% in the post-viremic patients. Only lymphopenia was reported in 70–80% of
confirmed cases in the outbreaks of La Reunion Island, with counts of 608 cells/mm3 during
the viremic phase. Leukocytosis had been associated with CHIKV infections in the past
[41,42]; however, none of the studies cited here found a significant increase in white cells.
Moreover, a significant decrease of these cells was observed in Win et al. (2010) and our study.
Limitations of our study must be considered. We obtained a biased sampling, including
only patients for one hospital because of the ease of obtaining samples from its clinics, thus,
not allowing for a sample that was truly representative of the general population. Another
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Table 4. Compilation of the most relevant clinical and abnormal laboratory features during different CHIKV outbreaks worldwide.
Publication Borgherini
et al. 2007
Staikowsky
et al. 2009*
Thiberville
et al. 2013
Reller
et al.
2013
Win et al.
2010
Nkoghe
et al.
2012
Mattar et al.
2015
Sahadeo
et al. 2015
Macpherson
et al. 2016
Location and date La Reunion
(2005–2006)
La Reunion
(2005–2006)
La Reunion
(2006)
Sri
Lanka
(2007)
Singapore
(2008)
Gabon
(2010)
Colombia
(2014)
Trinidad &
Tobago
(2014)
Grenada
(2014)
Total number of
patients included
157 274 76 797 97 270 100 158 493
CHIKV-positive patients
(%)
100 65.7 / 12.4 71.1 3.5 100 100 25.0 22.0 86.0
Genotype / Lineage ECSA (IOL) ECSA (IOL) ECSA (IOL) ECSA
(IOL)
Unknown ECSA Asian
(Caribbean)
Asian
(Caribbean)
Possibly Asian
Age (Mean or Median) 57.9 55.0 40.0 41 37.0 30.0 39 32 34.5
Male / Female
proportion
1.2 1.1 / 0.6 1.7 6.8 3.4 0.9 0.6 0.6 0.5
Days post- symptom
onset
2.1 1.8 / 6.2 1.2 3.0 2–4 2.0 2.9 2.4 -
Fever (%) 89.0 19.4 / 0.0 100 100 89.7 85.0 100 100 88.6
Arthralgia (%) 96.0 98.8 / 96.8 100 71.0 87.6 90.4 88 83.3 90.0
Myalgia (%) - 59.0 / 59.0 74.0 82.0 - 72.9 28 70.0 66.7
Headache (%) 47.1 70.0 / 58.8 72.0 75.0 - 71.8 64 76.7 53.9
Rash (%) 40.1 47.8 / 67.7 30–50 11.0 - 41.8 56 33.0 42.9
Digestive alterations
(%)¥
47.1 63.3 / 85.3 13–44 11.0–
38.0
- 32.0 4–6 16–26 26.9
Conjunctivitis (%) - 22.8 / 17.7 - 36.0 - - - - -
Adenopathy (%) 8.9 8.9 / 29.4 - 18.0 - - 8 - 28.8
Bleeding (%) 6.4 1.1 / 8.8 8.0 - 1.0 2.2 - 10.0 -
Arthritis 31.8 - - 0.0 - - - - -
Edema - 25.6 / 44.0 - - - - - - 25.1
High Creatinine
(>120 μmol/L)£
27.4% 111.1±73.1 /
104.2±1099
- - - 96.0±32.0 - - -
High AST (>37 U/L)£ 45.9% 55.0±164 /
53.2±42.3
28% - 3.0% 45.0±35 - - -
High ALT (>65 U/L)£ 16.6% 35.2±89.7 /
39.5±29.9
14.0% - 8.0% 33.0±17.0 - - -
High CRP (>3 mg/dL)£ 67.5% 5.6±5.0 / 3.1
±5.0
33.0% - - - - - -
Leukopenia (<4500
cells/mm3)£
5153±2198 5431±2139 /
5199±2554
- 4500 3500±1900 - - 6500±3250 -
Lymphopenia (<1000
cells/mm3)£
79% 608 ±314 /
1090±481
79.6% 1305 - 2228±216 - - -
Thrombocytopenia
(<100 x 103 platelets/
mm3)£
9.5% 174.2±56.0 /
173.7±62.2
24.0% 181.0 1.0% 233.1
±81.8
- 234.0±72.5 -
*This study reported values for viremic / post-viremic patientss.
£ Values may be represented as percentages or means / medians with their respective units depending on the measured parameter.
¥ Digestive alterations include abdominal pain, nausea, vomiting, and diarrhea.
Abbreviations: CHIKV, chikungunya virus; ECSA, Eastern/Central/Southern Africa; IOL, Indian Ocean lineage; AST, aspartate aminotransferase; ALT,
alanine aminotransferase; CRP, C reactive protein.
https://doi.org/10.1371/journal.pone.0186923.t004
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source of bias may be the enrollment of participants. The male/female ratio differed between
all patients recorded in the hospital and enrolled participant. Additionally, the age means
between all and recruited patients have also relevant difference between both sex, being in
males 36.2 and 42.7 years, respectively, while in females were 38.4 and 36.0 years, respectively.
Most of previous outbreaks have also faced similar limitations with sample collection, but they
were able to undertake meaningful evaluation of the clinical information such as we were able
too.
In conclusion, we describe the epidemiology and clinical features of CHIKV infection in
Southern Mexico. Clinical data of different outbreaks worldwide would be helpful for the
investigation of potential biomarkers for each of the phases of chikungunya fever and there-
fore, clinical diagnosis and treatment would be improved in viremic and immediate post-vire-
mic phase.
Supporting information
S1 File. Explanation of patient attention during the CHIKV outbreak in the hospital “Dr.
Roberto Nettel” of 2014–2015. This appendix clarifies how patients were asked for an oral
consent to provide blood samples keeping confidentiality of them as part of routine process of
epidemiological surveillance of febrile diseases outbreaks.
(PDF)
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